Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine
Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine
复制标题
纳武单抗对先前接受过肽疫苗治疗的转移性肾细胞癌患者具有显着的抗肿瘤作用
DOI：
10.1002/iju5.12139
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Kamba Tomomi
中科院分区：
文献类型：
--
作者：
Kurahashi Ryoma;Motoshima Takanobu;Fukushima Yumi;Murakami Yoji;Yatsuda Junji;Yamaguchi Takahiro;Sugiyama Yutaka;Fukushima Satoshi;Komohara Yoshihiro;Suekane Shigetaka;Kamba Tomomi
免疫检查点抑制剂和癌症特异性肽疫苗联合治疗的安全性和有效性尚未确定。病例介绍一名71岁女性转移性肾细胞癌患者，伴有多发性肺和胸膜转移。她先后接受干扰素α、舒尼替尼、阿西替尼和帕唑帕尼治疗，但未观察到临床疗效。她参加了一项使用癌症特异性肽疫苗治疗的临床试验。最初未观察到抗肿瘤作用，两个疗程后停止疫苗治疗。但在nivolumab开始治疗3个月后，在所有转移部位观察到显著的肿瘤缩小，这导致在6个月时几乎完全缓解。在10个月时，由于肽疫苗接种部位的蜂窝织炎，停止了纳武利尤单抗。有趣的是，即使在nivolumab停药后，完全反应维持了超过1 year.ConclusionWe经历了显着的抗肿瘤效果nivolumab在以前用疫苗治疗的患者。
IntroductionThe safety and efficacy of combination therapy comprising immune checkpoint inhibitors and cancer‐specific peptide vaccines have not yet been established.Case presentationA 71‐year‐old female metastatic renal cell carcinoma patient with multiple lung and pleural metastases. She had been treated with interferon alpha, sunitinib, axitinib, and pazopanib sequentially, but no clinical efficacy was observed. She participated in a clinical trial using cancer‐specific peptide vaccine therapy. Initially no antitumor effect was observed, and vaccine therapy was ceased after two courses. But 3 months after the start of nivolumab, remarkable tumor shrinkage was observed at all metastatic sites, which resulted in almost complete response at 6 months. At 10 months, nivolumab was stopped due to cellulitis at the peptide vaccine inoculation site. Intriguingly, even after nivolumab discontinuation, complete response was maintained for more than 1 year.ConclusionWe experienced a remarkable antitumor effect by nivolumab in a patient who was previously treated with vaccine therapy.